Atrium Therapeutics Inc (RNA) financials
Atrium Therapeutics revenue and earnings by year
Atrium Therapeutics's revenue was $18.6 million in the fiscal year to December 31, 2025, up 70.9% from the year before. Net income was -$49.5 million, -265.9% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 19 | 11 | 10 |
| Revenue growth | 70.9% | 11.6% | — |
| Operating income | -50 | -13 | -6 |
| Operating margin | -266.6% | -121.3% | -65.4% |
| Net income | -50 | -25 | -6 |
| Net margin | -265.9% | -230.5% | -65.4% |
| Free cash flow | -43 | -23 | 56 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open RNA in Markets.
See also:
No forecast, no recommendation. This page describes Atrium Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.